Amgen reported quarterly EPS of $5.15, topping the Zacks Consensus Estimate of $4.73 by $0.42 per share and improving from $4.90 a year ago. The earnings beat points to solid underlying fundamentals for the biotech company, with a modestly positive read-through for the stock.
Amgen reported quarterly EPS of $5.15, topping the Zacks Consensus Estimate of $4.73 by $0.42 per share and improving from $4.90 a year ago. The earnings beat points to solid underlying fundamentals for the biotech company, with a modestly positive read-through for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
